Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk Disease

Clinical trial NCT07272499 · RECRUITING

Trial details

NCT number: NCT07272499
Sponsor: Ruijin Hospital
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Mantle Cell Lymphoma (MCL)

Start date: 2025-09-10
Primary completion: 2028-09-10
Enrollment: 25

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.